Genetic Engineering Market Estimated to Witness a Staggering Growth by 2027

 

Global Genetic Engineering Market - Overview

The genetic engineering industry is expected to grow at a rapid pace. The factors influencing the growth of the market include increasing technologies for gene, widespread use of genetic engineering found in developed countries, special attention towards stem cells, increasing use of genetic engineering in medicine and various others.

Technology advanced products helps in treatment of various diseases. Organisms are also used for insulin production required for the treatment of patients suffering from diabetes. Hence, genetic engineering is expected to be an emerging technology in the field of medicine, enhancing the growth of this market. Increasing funding for research and development of medical products is further favouring the growth of the market. Global genetic engineering market is expected to reach USD 6.90 billion by 2027 at a CAGR of 12.48% during forecast period 2017 to 2027.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1528 

The market is forecasted to demonstrate a double digit growth by 2027, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2027.

Global Genetic Engineering Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Genetic engineering appears to be highly competitive and fragmented. With well-established market in the North America region major companies like Thermo Fisher Scientific Inc, Transposagen Biopharmaceuticals Inc., New England Biolabs, Genscript Biotech Corporation, Integrated DNA Technologies, Inc and various others have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

Thermo Fisher Scientific Inc. an American international biotechnology company founded in 2006 by the merger of Thermo Electronic and Fisher Scientific. In Feb 2014, the company announced the complete acquisition of Life Technology Corp for USD 76.13 Billion. Life Technology Corp is a global leading player in genetic testing and precision laboratory equipment. New instruments in genetic engineering technology are Ion S5 sequencing systems, Sanger sequencing, QuantStudio family, QuantiGene Plex Assay, QuantiGene Singleplex Assay and QuantiGene Singleplex HT Assay. This acquisition will help the company create unrivalled control in serving research, life sciences, specialty diagnostics and applied markets.

Merck KGaA is one of the world's leading supplier of materials and equipment in biotechnology sector. The company supplies all the equipments and products required in genetic engineering from bioreactors, cell lines and ultra-pure water of laboratories. To enlarge the life science division, the company in November 2015, announced the complete acquisition of Sigma-Aldrich with USD 17 billion. Merck's major research centers for medical biotechnology are located in Darmstadt (Germany), Beijing (China), Tokyo (Japan) and Boston (United States). “Centinel” technology is a combination of biologic solutions and advanced genetic editing technology. With this acquisition the company will increase its man power with 50,000 employees in more than 67 countries, working at 72 manufacturing sites worldwide.

Global Genetic Engineering Market - Regional Analysis

Global genetic engineering market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the global market for genetic engineering with more than 40% share of the total market in 2016. The major factor for the growth of the market include due to increasing use of genetic engineering in for the use of gene therapy, high incidence of cancer and neurological disorders like Alzheimer’s, dementia. Increasing awareness for the use of stem cells furthermore contribute influence the growth of market in North America.

Europe holds the second largest share of the global genetic engineering market. Asia Pacific is the fastest growing genetic engineering stimulation market across the globe. In Asia-Pacific there is wide range of opportunities for genetic engineering market due to the presence of developing countries, companies grabbing these opportunities and expanding their presence in the region. The developing countries in this region are widely adopting latest technologies in the field of genetic engineering. These rising development in the region is further influencing the growth of the market.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528

 

Vacuum Blood Collection Tube Market is expected to rise at a remarkable CAGR By 2027

 

Global vacuum blood collecting tube Market - Overview

The global vacuum blood collecting tube market sizt is growing exponentially owing to rising prevalence of chronic respiratory disease and increasing usage of combination therapy are the major factor driving the vacuum blood collecting tube Market. The global market for vacuum blood collection tube is expected grow at a CAGR of 7.5% over the forecasted period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1371 

The vacuum blood collection system consists of a double-pointed needle, a plastic holder or adapter, and a series of vacuum tubes with rubber stoppers of various colours. A vacuum blood collection tube is evacuated to create a vacuum inside the tube facilitating the draw of a predetermined volume of liquid. Most commonly used to collect blood samples in venipuncture, they are also used as urine collection tubes and as serum separator tubes. Vacuum Blood Collection Tube tubes may contain additives designed to stabilize and preserve the specimen prior to analytical testing. Tubes are available with or without a safety-engineered closure, with a variety of labelling options and closure colours as well as a range of draw volumes.

Vacuum collection tubes are glass or plastic tubes sealed with a partial vacuum inside by rubber stoppers. The air pressure inside the tube is negative, less than the normal environment. After inserting the longer needle into the vein, the phlebotomist pushes the tube into the holder so that the shorter needle pierces the stopper. The difference in pressure between the inside of the tube and the vein causes blood to fill the tube. The tubes are available in various sizes for adult and paediatric phlebotomies.

For additives, different blood tests requires different types of blood specimens. Most tubes have additives called anticoagulants which prevent clotting/coagulation of the blood. Plastic tubes may have an additive to enhance clotting of the blood. The anticoagulants are already in the tubes in the precise amount needed to mix with the amount of blood that will fill the tube. The colour of the stopper on each tube indicates if any anticoagulant is present in the tube. It is important to completely fill each tube so that the proportion of blood to chemical additive is correct, otherwise, the test results may not be accurate or the specimen will be rejected and will need to be recollected. It is also important to thoroughly mix the blood with the additive by gentle inversion.

The vacuum blood collection tube market is growing at an exponential rate. The cross infection occurring due to blood transfusion, blood donation leads to spread of infectious diseases which is anticipated to increase the demand for these products.

Global Vacuum Blood Collecting Tube Market - Regional Analysis

Depending on geographic region, Globally North America is the largest market for vacuum blood collecting tube. The North American market for vacuum blood collecting tube is expected to grow at a CAGR of 5.8% by the end of the forecasted period. These tubes may contain additional substances that preserve blood for processing in a medical laboratory. There is an increase in blood testing in these countries due to the prevalence new diseases.

Europe is expected to be the second-largest market for vacuum blood collecting tube which is expected to grow at a CAGR of 6.5%. It is used for blood culture and not for laboratory analysis, special collection to detect bacteria growing in blood.

Asia pacific region is expected to be fastest growing region in vacuum blood collecting tube market. Middle East & Africa is expected to have limited but steady growth in the market. These countries with the advancement of technology are expected to show large number of cases of infections and other hospital acquired disease which remain unnoticed currently.

Global Vacuum Blood Collecting Tube Market - Company Analysis

A vacuum blood collection tube is a sterile glass tube with a colored rubber stopper creating a vacuum seal inside of the tube which facilitate drawing predetermined volume of liquid, it is known as a Vacutainer. The vacutainer tubes were invented by Joseph Kleiner and Becton Dickinson in 1949. Vacutainer is a registered trademark of Becton Dickinson, which manufactures and sells the tubes ever since. The new gel vacuum tube seems to be an effective tool in the evacuated blood collection system due to its advantage in reduction of time in specimen processing.

Becton, Dickinson and Company (US), Sunphoria Co., Ltd. (Taiwan), Narang Medical Limited, CML Biotech, Bio – X, Labtech Disposables, Hebei Xinle Sci &Tech Co.,LTD (China), Sekisui Chemical Co. Ltd, HUMAN (US), Terumo (Japan), GBO, Medtronic (US), Sarstedt and others are some of the prominent players at the forefront of competition in the global vacuum blood collecting tube market and are profiled in MRFR Analysis. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/vacuum-blood-collection-tube-market-1371

 

DPT vaccine Market to Witness Widespread Expansion During 2020 to 2027

  Global Diphtheria Tetanus and Pertussis (DPT) vaccine Market - Overview

The Global Diphtheria, Pertussis, and Tetanus Vaccine Market Size is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.

There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1357 

Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.

However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.

Global DPT vaccine Market - Regional Analysis

Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.

The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.

Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.

Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.

The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.

Global DPT vaccine Market - Company Analysis

Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.

Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.

Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others are some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis. 

Browse More Details of the Report@ https://www.marketresearchfuture.com/reports/dpt-vaccine-market-1357 

Polyp Biopsy Market to Witness Widespread Expansion During 2020 to 2025

 

Market Analysis

Market Scenario

Polyp Biopsy Market is expected to grow with a healthy CAGR of 6.2% during the forecast period and reach USD 1,624.1 Million by 2025. Polyps are caused due to abnormal cell growth and are mostly benign. However, if they are left untreated, they could turn cancerous. Conclusively, there is a need to diagnose polyp to avoid cancer. For doing the same, biopsy is a major diagnostic procedure. In this procedure, a sample of tissue is removed from the polyp and is analyzed under the microscope.           

Rising incidences of polyps, growing geriatric populations, and increasing prevalence of colorectal cancer are projected to drive the market growth. Moreover, technological advancements related to biopsy is expected to fuel market growth. On the other hand, uncertain regulatory issues and biopsy-related risk of infections are expected to restrict the market growth during the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1673 

Global Polyp biopsy Market - Overview

Most of the medical conditions, including all cases of cancer must be diagnosed by taking a sample of tissue from the individual and sending it to a pathologist for diagnosis. This process is called biopsy. Polyps are normally found in organs with many blood vessels, organs include the uterus, colon, and nose. The global polyp biopsy market is expected to grow at a steady growth during the forecast period 2017-2022. The major factors influencing the growth of the market include rising consumption of tobacco and alcohol within the individuals, increasing prevalence of cancer across the globe and various others. The market is forecasted to demonstrate a single digit growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2022.

Global Polyp Biopsy Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of polyp biopsy appears to be highly competitive and fragmented. With well-established market in the North America region major companies have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

The market for biopsy has be highly competitive across the globe. Due to highly competitive are introducing new technology in for the development of the products. Caris Life Sciences one of the leading biotechnology company involved in manufacturing precision medicine, in December 2015 showcased the results from its first study using its revolutionary technology called Adaptive Dynamic Artificial Poly-ligand Targeting (ADAPT). The study presented, shows contains of blood plasma circulating complexes which contain information that could help as a diagnostic adjunct to mammography in women with dense breast tissue. In late 2015, outcomes from show that ADAPT is equally effective in difficult cases for which imaging technologies are inadequate for illustrating breast tissue as cancerous or non-cancerous. The ADAPT platform was developed on a huge library of approximately 1015 oligonucleotides engineered to adopt a highly complex set of unique three-dimensional binding sites. By introducing this technology will enhance the optimization of the aptamer library and testing on supplementary samples.

Global Polyp Biopsy Market - Regional Analysis

The global market is segmented into the various regions including Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas accounts for the largest market share of about more than ~40%. This large share can be attributed to favourable governmental conditions for research and development. CRC is the 3rd most common cancer and the third leading cause of cancer death in the United States. There has been increasing prevalence of adenomatous polyps of the colon and rectum both in the United States and various European countries.

Europe is the second largest market of polyp biopsy. Europe saw a high prevalent cases in the incidence of colorectal cancer (CRC) along with the over-all aging population as a whole. It has been found that there were more than 375,000 cases diagnosed and more than 203,000 deaths from this disease every year, making Europe’s the second most common cancer diagnosed patients and second most common cause of death due to cancer following lung cancer.

Asia Pacific due to raising of funds for research and development activities, and growing government initiatives for the awareness and preventive cancer. Asia Pacific is the fastest growing region in the global market. Particularly, India and China are anticipated to be a growing and the fastest growing market due to improvement in healthcare domain and increasing prevalence of cancer related diseases. Many major players seeking opportunity and expand their presence in this region influencing the growth of the market.   

The Middle East & Africa holds the least share in the polyp biopsy market due to lack of awareness, less emphasis on research and development activities, and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/polyp-biopsy-market-1673 

 

Global Ureteral Stents Market to Significant Growth Foreseen by 2025

 

Market Analysis

Ureteral stents are hollow & thin tubes that are inserted in ureters to treat or prevent obstacles during ‘urine-flow.’ They find applications in urological surgeries for retaining ureter patency & ensuring proper urinary-drainage. Ureteral stents are employed by the right end-users through various endourological procedures. They are mainly inserted with the help of cytoscopes. Multiple factors; like kidney stones, prostate cancers, and pre-operative patients draw the adoption of ureteral stents.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1389 

These stents enable the transport of remaining fragments without causing obstructions. Stents are also used for scratched ureters. Frankly, any kind of ureter surgery normally involves stents for ureter-treatments. Some other propellers of the ureteral stents market include tumors, bladder irregularities, & ureteral scarring/narrowing. With a rise in such cases, the global ureteral stents market analysis is set to grow at a substantial CAGR in the forecast period.

Propellers & Drawbacks

The ureteral stents market is mainly driven by all medical conditions that need these tubes. The world is experiencing a rise in kidney stones, because of certain factors. These factors encompass regular consumption of alcohol, animal proteins, calcium, vitamin supplements, etc. Of the different ‘kidney-stone’ treatments available, ureterorenoscopy & ureteroscopy observe the widest adoption of these stents, thereby driving the industry.

Alongside, kidney transplants propel market demand. All kidney replacement surgeries require ureteral stents inside the human body, till patients adjust to their new kidneys. Infection, dislocation, & obstruction complexities may result from the adoption of urinary stents, negatively impacting the market. Also, patients could experience discomfort or other problems while passing urine. All these factors urge research & development firms to create new products, slowing down the market.

Inactive lifestyles and aging population are important contributors to urinary disorders. Thus, both of them add to the usage of these stents, promoting market sales. Other factors affecting the market comprise unhealthy food, metabolic disorders, obesity, and dehydration. Novel smartphone applications are advantageous for doctors & patients, raising market expansion. Other hindrances that prevent further industry-progress are scarcity of proficient doctors and intricacies across extractions & placements.  

Classification and Regional Overview

The worldwide market is classified into materials, kinds, applications, and regions. Silicon, metal, hydrogel, plastic, polyurethane, etc. form the materials. The kinds encompass closed end, double pigtail, open end, and multiloop. Based on applications, the market consists of lithotripsy, ureterorenscopy, and others. Latin America, North America, Eastern Europe, Asia Pacific, Western Europe, and the Middle East & Africa constitute the geographies.

Emerging markets, such as Europe and North America are predicted to undergo swift expansion. Their increasing participants, research & developments, and urology incidences drive their sales. Asia Pacific would observe decent trends, as a consequence of its expanding medical infrastructure & supportive ‘patient-demographics.’  Asia Pacific is home to even more patients suffering from these diseases. With better fiscal conditions in India, China, and Brazil; majority of the business expansion could be ascribed to the collective demand from these nations. The Middle East specializes in advanced urology services.

Players and New Trends 

Prominent firms investing in the global ureteral stents market are Urovision, Allium Medical Solutions, Urotech, Teleflex, Mednova, and several others. Multiple advancements with regards to the design & growth of ureteral stents have seen the light of day. These innovations are aimed at lowering stent-related ‘side-effects.’  Some of these include infections, irritability, and bladder discomfort.

‘Bard Medical’ is another renowned manufacturer that helps medical experts in ureteroscopic, cystoscopic, & nephroscopic methods. The past years have witnessed design changes in the form of drug-eluting stents, drug-coated stents, and localized stenting. Thus, many of the eminent companies focusing on product innovations and regional expansion are bound to generate higher revenues & recognition.    

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ureteral-stents-market-1389 

 

Ovulation Test Market is expected to rise at a remarkable CAGR By 2025

 

Global Ovulation Test Market - Overview

Ovulation is the biological process that results in the release of eggs from the ovary. The ovulation test detects a rise in luteinizing hormone (LH) in the urine. This rise in the hormone signals the ovary to release the egg. This test is often used by women to help predict when an egg release is likely. This is when pregnancy is most likely to occur. Moreover, these ovulation prediction kits or OPKs are also being used to detect the exact day of ovulation for those women that undergo a treatment for infertility. There is an increase in the demand of ovulation test kits across the globe. Urine test segment accounts for the largest market share due to its extensive application by women for testing pregnancy.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1341 

The global ovulation test market is growing with the steady pace. The global ovulation test market is expected to grow at a CAGR of ~4.5% during the forecast period 2017-2023. According to a recent study report published by the Market Research Future, The global ovulation test market is booming and expected to gain prominence over the forecast period growing rapidly due to rising technology driven ovulation monitors. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).

The market is expected grow with the same trends during the forecast period. The major drivers will be technological advancement for reliable and accurate results from ovulation test kits has spurred the growth the market.  According to the Centers for Disease Control, one in eight women has trouble conceiving or sustaining a pregnancy, due to age, health issues or other factors. For that, companies are introducing advanced kits which will help them to monitor their pregnancy and ovulations. For instance, apps like Glow and Apple's own Reproductive Health kit in iOS make it easier to record, visualize and aggregate large amounts of data related to the reproductive health of the patients.  Moreover, pregnancy management and women and child health gaining importance throughout the world favor the growth of this market. Increase in first pregnancy, complications during pregnancy and demand of reliable technology for pregnancy test kits.

Global Ovulation Test Market - Competitive Analysis

The ovulation test kit market is characterised by the presence of several well-established and small players, the global market of ovulation test appears to be getting competitive in this region due to increasing first time pregnancy age and gynaecological disorders. Global players are increasingly expanding their footprint in the emerging nations, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to increase with time during the forecast period. Well established players are entering into new product launches in order to gain competitive edge in this market and to maintain their market position.    

Companies like in April 2016, Church & Dwight Co., Inc. has launched a First Response Pregnancy PRO Digital Pregnancy Test + App Access. It is the first and only Bluetooth enabled pregnancy test stick which will be available nationwide. This will help the company add-on a product to their portfolio and help to increase the customer base.

Moreover, Prestige Brands Holdings Inc., in December 2016, has announced to acquire C.B Fleet Company which manufactures products for feminine care to reach in global market.   Furthermore, Swiss Precision Diagnostics a market leader across the globe with wide range of women health brands out of which Accu clear provides a range of products for pregnancy and ovulation test. It has been granted three patents by the U.S. in advanced clear blue ovulation test helping it to maintain its leading position in the market.

This particular market is focussing on product launches and acquisitions as a key strategy, thereby presenting a potential opportunities for the growth of the market.

Swiss Precision Diagnostics GmbH (Switzerland), Church & Dwight Co. Inc. (U.S.), Prestige Brands Holdings Inc. (U.S.), HiLin Life Products Inc. (U.S.) and Fairhaven Health LLC (U.S.). Other players in this market are: Fertility Focus Limited (U.K.), Geratherm Medical AG (Germany), Accuquik (California), NecLife (India) and Piramal Healthcare (India) are some of the prominent players at the forefront of competition in the Global Ovulation Test Market and are profiled in MRFR Analysis. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ovulation-test-market-1341

 

Biosimilars Market is expected to rise at a remarkable CAGR By 2023

  Biosimilars Market Scenario

Biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1329 

For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.

For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)

Biosimilars Market Segmentation

Global Biosimilars Market has been segmented based on product, applications, end users, and region.

The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.

The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin

The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  

For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.

On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.

For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.

Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.

Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.

The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Biosimilars Market Key Players

The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).

Regional Market Summary

The market in Europe is expected to dominate the global biosimilars market due to the increasing biosimilar product approvals and the emergence of new market participants in the region. The growing prevalence of chronic diseases in the US and Canada is expected to drive the market growth. Furthermore, there has been an increase in the expenditure in research by healthcare bodies; this is expected to fuel the growth of the market in this region. For example, according to Amgen, in 2019, Europe has an advanced biosimilar market, with 53 approved biosimilar products. The market in Asia-Pacific expected to show a considerable amount of growth. This can be attributed to the patent expiry of biologic products, introduction of new biosimilars, adoption of biosimilars to reduce the treatment cost, and the involvement of key companies. For instance, according to the National Center for Biotechnology Information, in 2019, Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop similar biologics. Already there are more than 100 Indian biopharmaceutical companies are engaged in manufacturing and marketing of biosimilar. The market in Americas is projected to have a steady growth rate during the forecast period owing to an increase in chronic diseases and well-developed healthcare system. The market in the Middle East & Africa is projected to account for the least Biosimilars Market share of the global market due to low disposable income in the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329